Involvement of B lymphocytes in the growth inhibition of human pulmonary melanoma metastases in athymic nu/nu mice by an antibody-lymphotoxin fusion protein.
Antibody-cytokine fusion proteins can target biologically active cytokines to various tumor sites, achieving local concentrations sufficient to induce host immune responses leading to tumor elimination. Here, we demonstrate the therapeutic efficacy of a tumor-specific antibody-lymphotoxin fusion protein (ch225-LT) on xenografted pulmonary metastases of human melanoma. In vitro studies indicated a direct cytotoxic effect of such construacts on melanoma cells via the induction of apoptosis, as demonstrated by cell cycle analysis and DNA fragmentation. However, ch225-LT lacked any therapeutic effect in immune deficient C.B17 scid/beige and scid/scid mice, indicating the insufficiency of this direct mechanism in vivo. In contrast, in athymic nu/nu mice, ch225-LT completely inhibited outgrowth of the xenografted tumor. This therapeutic effect was accompanied by infiltrations of CD45+, Mac-1+, and asialo-GM1+ cells into the tumor; B220+ cells were present in the surrounding tissue and the periphery of the tumor. The functional role of asialo-GM2+ cells was confirmed by in vivo depletion studies. Our data indicate that an antibody-lymphotoxin fusion protein effectively inhibits the growth of disseminated melanoma metastases by mechanisms that function in the absence of mature T cells, but require B, NK, and other asialo-GM1+ cells.
Reisfeld
R A
RA
Department of Immunology, The Scripps Research Institue, La Jolla, CA 92037, USA.
Gillies
S D
SD
Mendelsohn
J
J
Varki
N M
NM
Becker
J C
JC
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D017209:Apoptosis; D001402:B-Lymphocytes / Q000276:immunology*; D002453:Cell Cycle; D016923:Cell Death; D002455:Cell Division / Q000187:drug effects; D004249:DNA Damage; D006801:Humans; D007150:Immunohistochemistry; D000922:Immunotoxins / Q000627:therapeutic use*; D007249:Inflammation; D008175:Lung Neoplasms / Q000276:immunology / Q000473:pathology / Q000556:secondary* / Q000628:therapy*; D008212:Lymphocyte Depletion; D008233:Lymphotoxin-alpha / Q000627:therapeutic use*; D008545:Melanoma / Q000276:immunology / Q000473:pathology / Q000556:secondary* / Q000628:therapy*; D051379:Mice; D008819:Mice, Nude; D016513:Mice, SCID; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D013045:Species Specificity; D014183:Transplantation, Heterologous
D000911:Antibodies, Monoclonal; D000922:Immunotoxins; D008233:Lymphotoxin-alpha; D011993:Recombinant Fusion Proteins